SCHEMBL19059485

SCHEMBL19059485

CCC/C=C(\C=C/N)C(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.32
GRIK2 Q13002 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19803848 0.82
SCHEMBL9311554 0.75 ALDH1A1 (0.39) GRIK1GRIK2
SCHEMBL9311557 0.75 ALDH1A1 (0.39) GRIK1GRIK2
SCHEMBL19274375 0.74 BACE1 (0.32) GRIK1GRIK2
SCHEMBL26762299 0.71
SCHEMBL19050432 0.71
SCHEMBL18727673 0.70
SCHEMBL20365820 0.70
SCHEMBL18387064 0.70 GRIK1 (0.33) GRIK1GRIK2
SCHEMBL25575007 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117271-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-04-20 US disclosed
US-20230054084-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20220069241-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2022-03-03 US disclosed
US-10011573-B2 Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-07-03 US disclosed
US-9745257-B2 Phenyl-guanidine derivatives UNIVERSIDAD NACIONAL DE QUILMES (AR) 2017-08-29 US disclosed
US-20170183319-A1 HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011573-B2 Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use AR, SHBG, BRCA1 GRIK1 2854/4885GRIK2 3215/4885
US-20220069241-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES CHRM1, LBR, CNKSR1 GRIK1 557/4885GRIK2 958/4885
US-20230054084-A1 COMPOUNDS AND METHODS OF USE XDH, LPXN, F12 GRIK1 2419/4885GRIK2 2784/4885
US-20170183319-A1 HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE AR, FSHR, ESRRB GRIK1 2577/4885GRIK2 2737/4885
US-20230117271-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, OCIAD2, ODC1 GRIK1 1710/4885GRIK2 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.